Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan - Results from domestic baseline data of the REduction of atherotherombosis for continued health (REACH) registry

被引:59
作者
Yamazaki, Tsutomu
Goto, Shinya
Shigematsu, Hiroshi
Shimada, Kazuyuki
Uchiyama, Shinichiro
Nagai, Ryozo
Yamada, Nobuhiro
Matsumoto, Masayasu
Origasa, Hideki
Bhatt, Deepak L.
Steg, P. Gabriel
Ikeda, Yasuo
机构
[1] Univ Tokyo, Dept Clin Epidemiol & Syst, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan
[2] Tokai Univ, Sch Med, Dept Med, Kanagawa, Japan
[3] Tokyo Med Univ, Dept Vasc Surg, Tokyo, Japan
[4] Tokyo Womens Med Univ, Dept Neurol, Tokyo, Japan
[5] Univ Tokyo, Dept Cardiol, Tokyo, Japan
[6] Univ Tsukuba, Inst Clin, Dept Internal Med, Ibaraki, Japan
[7] Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, Hiroshima, Japan
[8] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA
[9] Toyama Univ, Dept Biostat, Toyama, Japan
[10] Hop Bichat Claude Bernard, Dept Cardiol, F-75877 Paris 18, France
[11] Keio Univ, Dept Med, Sch Med, Tokyo, Japan
关键词
atherothrombosis; japan; REACH; risk factors;
D O I
10.1253/circj.71.995
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The REduction of Atherothrombosis for Continued Health (REACH) Registry is an international observational study of patients with, or at risk of, atherothrombotic disease. Japanese patients were analyzed to clarify national prevalence and treatment. Methods and Results Almost 68,000 outpatients were recruited worldwide with 5,193 in Japan. Among the Japanese patients, 83.7% had established vascular disease (symptomatic) and 16.3% had risk factors only (asymptomatic). Of the symptomatic patients, 14.0% had atherothrombotic lesions in more than I vascular bed, with 0.8% having lesions in 3 areas: brain, heart, and peripheral arteries. The prevalence of additional atherothrombotic risk factors among symptomatic patients was independent of the vascular lesion. Obesity was recorded in 10.6% and 42. 1 % of patients according to the National Cholesterol Education Program and Japanese guidelines, respectively. Pharmacologic intervention for risk factors was inadequate: only 37.7% of diabetic patients received antidiabetic medication, 79.6% of hypertensive patients used antihypertensives, and 74.0% received antiplatelet agents. The use of statins (44.1 %) and aspirin (54.7%) was less common than seen in REACH globally. Conclusions Japanese patients enrolled in REACH share many similarities with the global population, but with some important differences. Long-term follow-up will determine the impact of these factors on the development of atherothrombotic events.
引用
收藏
页码:995 / 1003
页数:9
相关论文
共 22 条
  • [1] [Anonymous], WORLD HLTH REP 2002
  • [2] Racial heterogeneity in coronary artery vasomotor reactivity: Differences between Japanese and Caucasian patients
    Beltrame, JF
    Sasayama, S
    Maseri, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (06) : 1442 - 1452
  • [3] International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
    Bhatt, DL
    Steg, PG
    Ohman, EM
    Hirsch, AT
    Ikeda, Y
    Mas, JL
    Goto, S
    Liau, CS
    Richard, AJ
    Röther, J
    Wilson, PWF
    Andersen-Dalheim, H
    Anderson, P
    Anell, B
    Arber, S
    Armstrong, K
    Arnot, D
    Baldam, A
    Barratt, I
    Barresi, S
    Beder, J
    Benson, M
    Bergman, F
    Best, J
    Bhasim, R
    Bovell, G
    Bowman, N
    Brkic, M
    Bromberger, D
    Brown, D
    Brown, J
    Brownstein, M
    Bruce, A
    Buonopane, J
    Burns, S
    Butler, A
    Byrne, D
    Carson, J
    Cassimatis, P
    Chaffey, G
    Chambers, D
    Chan, WJ
    Chan, B
    Cheatham, J
    Chen, R
    Cheong, B
    Cheung, C
    Chin, J
    Chiu, A
    Choo, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (02): : 180 - 189
  • [4] Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999 - The Framingham Heart Study
    Fox, CS
    Evans, JC
    Larson, MG
    Kannel, WB
    Levy, D
    [J]. CIRCULATION, 2004, 110 (05) : 522 - 527
  • [5] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
    Gent, M
    Beaumont, D
    Blanchard, J
    Bousser, MG
    Coffman, J
    Easton, JD
    Hampton, JR
    Harker, LA
    Janzon, L
    Kusmierek, JJE
    Panak, E
    Roberts, RS
    Shannon, JS
    Sicurella, J
    Tognoni, G
    Topol, EJ
    Verstraete, M
    Warlow, C
    [J]. LANCET, 1996, 348 (9038) : 1329 - 1339
  • [6] Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding
    Goto, Shinya
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (04) : 3 - 11
  • [7] Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
    Grundy, SM
    Cleeman, JI
    Daniels, SR
    Donato, KA
    Eckel, RH
    Franklin, BA
    Gordon, DJ
    Krauss, RM
    Savage, PJ
    Smith, SC
    Spertus, JA
    Costa, F
    [J]. CIRCULATION, 2005, 112 (17) : 2735 - 2752
  • [8] Hayashi D, 2004, JPN HEART J, V45, P895
  • [9] KATSUKI S, 1964, JPN HEART J, V5, P12
  • [10] Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study
    Liu, J
    Hong, YL
    D'Agostino, RB
    Wu, ZS
    Wang, W
    Sun, JY
    Wilson, PWF
    Kannel, WB
    Zhao, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (21): : 2591 - 2599